However, patients with high-risk features such as rapidly progressing disease require prompt treatment to manage symptoms and reduce organ damage.Ibrutinib is a specialized anti-cancer therapy that targets the Bruton's tyrosine kinase (BTK, an enzyme important in the development of CLL).